caa a22 4500 469116803 CHVBK 20180323133127.0 cr unu---uuuuu 170328e19920601xx s 000 0 eng 10.1007/BF00172764 doi (NATIONALLICENCE)springer-10.1007/BF00172764 Treatment of recurrent metastatic medulloblastoma with intensive chemotherapy and allogeneic bone marrow transplantation [Elektronische Daten] [Joel Lundberg, David Weissman, Peter Beatty, Robert Ash] We report here the first known case of a patient with recurrent metastatic medulloblastoma to achieve long-term disease-free survival following treatment with allogeneic bone marrow transplantation. A 27 year old white male with recurrent metastatic medulloblastoma involving lymph nodes, bone and bone marrow was treated with multi-agent chemotherapy followed by allogeneic bone marrow transplantation from an HLA-identical sibling donor. Morbidity was acceptable with moderate to severe mucositis in the immediate post transplant period and clinical grade I graft versus host disease of the skin controlled with modest doses of corticosteroids. The patient continues in unmaintained complete remission in excess of 28 months with a performance status of 100%. Allogeneic marrow transplantation following cytoreductive salvage chemotherapy is an aggressive strategy that may offer an improved likelihood of disease eradication and ultimate cure for poor prognosis patients with recurrent metastatic medulloblastoma. Kluwer Academic Publishers, 1992 medulloblastoma nationallicence allogeneic nationallicence bone marrow transplantation nationallicence Lundberg Joel Departments of Medicine, and the Bone Marrow Transplantation Program of the Medical College of Wisconsin, 53226, Milwaukee, Wisconsin, USA aut Weissman David Departments of Medicine, and the Bone Marrow Transplantation Program of the Medical College of Wisconsin, 53226, Milwaukee, Wisconsin, USA aut Beatty Peter Departments of Medicine, and the Bone Marrow Transplantation Program of the Medical College of Wisconsin, 53226, Milwaukee, Wisconsin, USA aut Ash Robert Departments of Medicine, and the Bone Marrow Transplantation Program of the Medical College of Wisconsin, 53226, Milwaukee, Wisconsin, USA aut Journal of Neuro-Oncology Kluwer Academic Publishers 13/2(1992-06-01), 151-155 0167-594X 13:2<151 1992 13 11060 https://doi.org/10.1007/BF00172764 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00172764 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lundberg Joel Departments of Medicine, and the Bone Marrow Transplantation Program of the Medical College of Wisconsin, 53226, Milwaukee, Wisconsin, USA aut NATIONALLICENCE 700 1- Weissman David Departments of Medicine, and the Bone Marrow Transplantation Program of the Medical College of Wisconsin, 53226, Milwaukee, Wisconsin, USA aut NATIONALLICENCE 700 1- Beatty Peter Departments of Medicine, and the Bone Marrow Transplantation Program of the Medical College of Wisconsin, 53226, Milwaukee, Wisconsin, USA aut NATIONALLICENCE 700 1- Ash Robert Departments of Medicine, and the Bone Marrow Transplantation Program of the Medical College of Wisconsin, 53226, Milwaukee, Wisconsin, USA aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 13/2(1992-06-01), 151-155 0167-594X 13:2<151 1992 13 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer